Subject(s)
Escherichia coli Infections/microbiology , Escherichia coli/genetics , Klebsiella Infections/microbiology , Klebsiella pneumoniae/genetics , Drug Resistance, Multiple, Bacterial , Escherichia coli/drug effects , Escherichia coli Infections/drug therapy , Escherichia coli Proteins/genetics , Humans , Infant , Klebsiella Infections/drug therapy , Klebsiella pneumoniae/drug effects , Male , Microbial Sensitivity Tests , beta-Lactamases/geneticsSubject(s)
Bacterial Proteins/analysis , Cross Infection/diagnosis , Genotype , Klebsiella Infections/diagnosis , Klebsiella pneumoniae/classification , Molecular Typing , beta-Lactamases/analysis , Adult , Anti-Bacterial Agents/pharmacology , Cross Infection/microbiology , Female , Hospitals , Humans , Italy , Klebsiella Infections/microbiology , Klebsiella pneumoniae/enzymology , Klebsiella pneumoniae/genetics , Klebsiella pneumoniae/isolation & purification , Microbial Sensitivity TestsABSTRACT
Class II transactivator (CIITA) induces transcription of major histocompatibility complex (MHC) II genes and can potentially be used to improve genetic immunotherapies by converting non-immune cells into cells capable of presenting antigens to CD4+ T cells. However, CIITA expression is tightly controlled and it remains unclear whether distinct non-immune cells differ in this transactivator regulation. Here we describe the development of gene delivery systems capable of promoting the efficient CIITA expression in non-immune cell lines and in primary human cells of an ex vivo skin explant model. Different human cell types undergoing CIITA overexpression presented high-level de novo expression of MHC II, validating the delivery systems as suitable tools for the CIITA evaluation as a molecular adjuvant for gene therapies.
Subject(s)
Gene Transfer Techniques , Genes, MHC Class II , Trans-Activators/genetics , Genetic Therapy/methods , Genetic Vectors/genetics , HEK293 Cells , HeLa Cells , Humans , Lentivirus/genetics , Skin/metabolism , Trans-Activators/metabolismABSTRACT
Saccharomyces boulardii is the only yeast approved as a probiotic for human consumption. Here, we report the draft genome sequence of the strain ATCC MYA-796, derived from the French Ultra Levure probiotic drug. The genome has a size of 11.6 Mb with 5,305 putative open reading frames predicted.
